Gabriel Martinez, Ph.D., is the Chief Scientific Officer and Co-Founder of Pretzel Therapeutics, a biotech company focused on mitochondrial medicine. With a Ph.D. from Queen Mary University of London and a B.Sc. from Universitat de Barcelona, he brings over 20 years of drug development experience. He previously held leadership roles at Praxis Precision Medicines, Sage Therapeutics, AstraZeneca, and Vertex Pharmaceuticals. At Pretzel, he leads scientific strategy and innovation, recently overseeing the launch of PX578 into Phase 1 trials—a promising therapy targeting POLG to treat mitochondrial DNA depletion syndromes and neurodegenerative diseases like Parkinson’s and Alzheimer’s.